tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
Weekend UpdatesInsiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
20h ago
AGX
EYPT
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
PremiumCompany Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
12d ago
8K
EYPT
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
PremiumCompany Announcements
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
1M ago
8K
EYPT
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
PremiumCompany Announcements
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
1M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
1M ago
EYPT
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
PremiumRatingsEyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
2M ago
EYPT
EyePoint price target raised to $35 from $31 at Citi
Premium
The Fly
EyePoint price target raised to $35 from $31 at Citi
2M ago
EYPT
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
Premium
Company Announcements
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
2M ago
EYPT
EyePoint price target raised to $30 from $23 at H.C. Wainwright
PremiumThe Fly
EyePoint price target raised to $30 from $23 at H.C. Wainwright
2M ago
EYPT
EyePoint price target raised to $29 from $27 at Chardan
PremiumThe Fly
EyePoint price target raised to $29 from $27 at Chardan
2M ago
EYPT
EyePoint reports Q4 EPS (81c), consensus (75c)
PremiumThe Fly
EyePoint reports Q4 EPS (81c), consensus (75c)
2M ago
EYPT
EyePoint expects cash to fund operations into Q4 2027
PremiumThe Fly
EyePoint expects cash to fund operations into Q4 2027
2M ago
EYPT
EyePoint Starts Global Phase 3 Trials for DURAVYU
PremiumCompany AnnouncementsEyePoint Starts Global Phase 3 Trials for DURAVYU
2M ago
8K
EYPT
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
Premium
The Fly
EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU
2M ago
EYPT
Is EYPT a Buy, Before Earnings?
Premium
Pre-Earnings
Is EYPT a Buy, Before Earnings?
2M ago
EYPT
EyePoint price target raised to $36 from $33 at Mizuho
PremiumThe Fly
EyePoint price target raised to $36 from $33 at Mizuho
2M ago
EYPT
EyePoint appoints Campbell as Chief Commercial Officer
PremiumThe Fly
EyePoint appoints Campbell as Chief Commercial Officer
2M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
2M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
3M ago
EYPT
EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
PremiumRatingsEyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
4M ago
EYPT
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
Premium
The Fly
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
4M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
Premium
The Fly
EyePoint reports inducement grants under NASDAQ listing rule
4M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >